FOXP3 and non-small cell lung carcinoma: In order to determine if CCR8+ FOXP3− Tconv cells are enriched in human tumors, we analyzed CD4+ T cells from 48 patents with non-small cell lung carcinoma (NSCLC) by flow cytometry (Fig. S6).